Prosecution Insights
Last updated: October 04, 2026
Application No. 17/791,684

COMPLEXES OF N-HETEROCYCLIC CARBENES FOR TRANSITION METAL CATALYSIS

Final Rejection §112
Filed
Jul 08, 2022
Priority
Jan 08, 2020 — provisional 62/958,583 +2 more
Examiner
CHEN, PO-CHIH
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Rutgers, The State University of New Jersey
OA Round
4 (Final)
74%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
572 granted / 771 resolved
+14.2% vs TC avg
Moderate +15% lift
Without
With
+14.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
51 currently pending
Career history
806
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
33.4%
-6.6% vs TC avg
§102
19.0%
-21.0% vs TC avg
§112
30.8%
-9.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 771 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This office action is a response to Applicant’s amendments/remarks after non-final rejection filed 6/24/2026. As filed, claims 1, 2, 5, 7, 10-12, 14, and 15 are pending; claims 16, 17, 20, and 21 are withdrawn; and claims 3, 4, 6, 8, 9, 13, 18, 19, and 22-26 are cancelled. Response to Amendments/Remarks Applicant’s amendments/remarks, filed 6/24/2026, with respect to claims 1, 2, 5, 7, and 10-15, have been fully considered and are entered. The status for each rejection in the previous Office Action is set out below. The § 112(b) indefinite rejection of claims 1, 5, 7, 10, and 13-15 is withdrawn per amendments and cancellation of claim 13. The claim objection of claim 11 is withdrawn per amendments The claim objection of claim 13 is withdrawn per cancellation of the claim. The claim objection of claims 2 and 12 is withdrawn per amendments. Election/Restrictions Claims 1, 2, 5, 7, 10-12, 14, and 15 are directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claims 16, 17, 20, and 21, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104. Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement as set forth in the Office action mailed on 4/3/2025 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 16, 17, and 21 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 16, the claim is dependent of claim 1, and the claim recites the limitation of “p is 0, 1, 2, 3, 4, or 5”. In claim 1, p cannot be 0. Having p = 0 in claim 16 introduces ambiguity into the metes and bounds of this claim, which rendered this claim indefinite. Regarding claim 17, the claim is dependent of claim 16, and it failed to correct the indefiniteness issue of claim 16, which rendered the claim indefinite. Regarding claim 21, the claim recites the phrase, “The method of claim 21”. Claim 21 cannot be dependent of itself. By doing so, it creates ambiguity into the metes and bounds of this claim, which rendered the claim indefinite. Claim Objections Claims 16 and 21 are objected to because of the following informalities: Regarding claim 16, the claim recites multiple instances of “OSiR3” for instant variable R9. Accordingly, the duplicate needs to be removed. Regarding claim 16, the claim recites the phrase, “C1-12 alkylalkyl”, for instant variable R9, which contains typographical error, and it needs to be corrected. Regarding claim 21, the claim recites the phrase, “the contacting is in the presence of a base”. Such expression can be clarified by reciting -- the contacting is in --. Appropriate correction is required. Allowable Subject Matter Claims 1, 2, 5, 7, 10-12, 14, 15, and 20 are allowed. Conclusion Claims 16, 17, and 21 are rejected. Claims 1, 2, 5, 7, 10-12, 14, 15, and 20 are allowed. Claims 16 and 21 are objected. Claims 3, 4, 6, 8, 9, 13, 18, 19, and 22-26 are cancelled. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to PO-CHIH CHEN whose telephone number is (571)270-7243. The examiner can normally be reached Monday - Friday 10:00 am to 6:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at (571)270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PO-CHIH CHEN/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Show 1 earlier event
Jul 02, 2025
Non-Final Rejection mailed — §112
Sep 19, 2025
Response Filed
Nov 19, 2025
Final Rejection mailed — §112
Feb 18, 2026
Request for Continued Examination
Feb 24, 2026
Response after Non-Final Action
Mar 24, 2026
Non-Final Rejection mailed — §112
Jun 24, 2026
Response Filed
Sep 09, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12729209
MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT
3y 5m to grant Granted Sep 08, 2026
Patent 12715852
PREPARATION OF OPTICALLY ACTIVE ENANTIOMERS OF PIPERONYL AMINES BY RESOLUTION OF THE DIASTEREOMERIC SALTS
3y 11m to grant Granted Aug 25, 2026
Patent 12714693
USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS
1y 8m to grant Granted Aug 25, 2026
Patent 12703676
SYSTEMS AND METHODS FOR PRODUCING NITRILES
2y 2m to grant Granted Aug 11, 2026
Patent 12691101
NOVEL COMPOUND AND METHOD FOR PREVENTING OR TREATING OF RESPIRATORY DISEASES COMPRISING THE SAME AS AN ACTIVE INGREDIENT
4y 9m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
74%
Grant Probability
89%
With Interview (+14.8%)
2y 5m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 771 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month